News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Rheonix, Inc. Receives $500,000 From National Science Foundation to Expand Scope of Automated Molecular Detection System

11/7/2013 8:59:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has received a $500,000 Small Business Innovation Research (SBIR) Phase IIB grant from the National Science Foundation (NSF). The funding adds to the $650,000 the company previously received in NSF SBIR Phase I, Phase IB and Phase II funding for this project and will allow Rheonix to expand the capabilities of its pathogen detection system from the evaluation of recreational water to detection of pathogens in food and beverage markets.

The Phase IIB funding was granted based on a joint development agreement recently entered into by Rheonix and Life Technologies, a global leader in the life sciences tools and diagnostic markets. Under the agreement, Rheonix is developing a platform with built-in capabilities for the in vitro diagnostics market and will supply its CARD® technology to Life Technologies for an automated testing platform in applied markets such as food testing. The partnership will significantly shorten the time necessary for Rheonix to enter the clinical market with its sample-to-result molecular diagnostic instrument.

“The added funding by NSF further validates the scientific merit of our platform,” said Tony Eisenhut, president of Rheonix. “In addition, having a strategic partner of the stature of Life Technologies was a definite benefit during our discussions with NSF. As we have established the strategic partnership with Life Technologies in the applied markets, we also continue to explore such partnerships in other markets of interest to us, especially human clinical diagnostics.”

For the clinical market, the walk-away Rheonix platform is fully automated and addresses the most difficult challenges facing the health care industry today, including workforce shortages, limited access to advanced molecular testing and escalating costs. Once a raw sample is placed on the Rheonix CARD, the automated platform runs with no user intervention through the process of sample extraction, DNA purification, amplification and detection. This eliminates the need for multiple pieces of existing equipment, helping make the testing process quicker, more efficient, less expensive and less likely to result in human error.

“We are excited that the NSF has provided funding to continue to assist us in developing and expanding the scope of our fully automated molecular detection platform,” said Richard Montagna, Ph.D., senior vice president for scientific affairs at Rheonix and the project’s principal investigator. “NSF is focused on moving technologies into commercial applications, and they recognized the value of our Life Technologies partnership and its reach into the applied markets.”

The NSF SBIR Program is designed to stimulate technological innovation in the private sector by strengthening the role of small business concerns in meeting federal research and development needs and increasing the commercial application of federally supported research results.

For more information, please visit or

About the National Science Foundation

The National Science Foundation (NSF) is an independent federal agency that supports fundamental research and education across all fields of science and engineering. In fiscal year (FY) 2012, its budget was $7.0 billion. NSF funds reach all 50 states through grants to nearly 2,000 colleges, universities and other institutions. Each year, NSF receives about 50,000 competitive requests for funding, and makes about 11,500 new funding awards. NSF also awards about $593 million in professional and service contracts yearly.

About Rheonix, Inc.

Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx™ platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus